Compass Therapeutics Investor Presentation Deck
DISCLAIMER
This presentation has been prepared by Compass Therapeutics, Inc. ("we," "us," "our," or the "Company"). Statements contained herein are made as of the date of this presentation unless stated
otherwise, and this presentation shall not under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or
revised to reflect information that subsequently becomes available or changes occurring after the date hereof.
This presentation includes forward-looking statements regarding our drug candidates, the timing of the start and conclusion of ongoing or planned clinical trials, including the potential impact of the
ongoing COVID-19 pandemic on our business, the timing and outcome of regulatory decisions, future availability of clinical trial data, our collaborations for our product candidates and the maintenance of
those collaborations, business and results from operations, and other matters. Actual results could differ materially from those contained in any forward-looking statements as a result of various factors,
including without limitation: that our drug candidates do not advance in development or result in approved products on a timely or cost effective basis or at all; the cost, timing and results of clinical trials;
our ability to manage and mitigate the impact of the ongoing COVID-19 pandemic; that many drug candidates that have completed early-stage trials do not become approved drugs on a timely or cost
effective basis or at all; the ability to enroll patients in clinical trials; possible safety and efficacy concerns; regulatory developments; our ability to protect our intellectual property rights, and unexpected
costs, charges or expenses that reduce cash runway. Our pipeline programs are in various stages of pre-clinical and clinical development, and the process by which such pre-clinical or clinical
therapeutic candidates could potentially lead to an approved therapeutic is long and subject to significant risks and uncertainties. These and other risks and uncertainties that we face are described in our
most recent Annual Report on Form 10-K, and in other filings that we make with the Securities and Exchange Commission from time to time. We undertake no obligation to update forward-looking
statements as result of new information or otherwise.
This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about our industry. This data involves a
number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions, and estimates of our future performance and the future
performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk.
This presentation concerns drugs that are under clinical investigation, and which have not yet been approved for marketing by the U.S. Food and Drug Administration (FDA). It is currently limited by
Federal law to investigational use, and no representation is made as to its safety or effectiveness for the purposes for which it is being investigated.
COMPASS
THERAPEUTICS
2View entire presentation